Alembic Pharmaceuticals saw a dip of over 2% in its shares following the announcement of Q4FY25 results. As of 2:08 PM, the shares were trading 1.94% down at Rs 887.85.
Despite this, the company reported a solid 17% year-on-year (YoY) growth in consolidated net revenue, reaching ₹1,769.64 crore, up from ₹1,516.98 crore in Q4FY24. However, net profit for the quarter decreased slightly to ₹156.89 crore from ₹178.21 crore YoY, primarily due to higher expenses. This, however, represented an improvement over the ₹138.42 crore reported in Q3FY25.
For the full financial year FY25, Alembic posted total revenue of ₹6,714.63 crore, a 7% increase from ₹6,256.93 crore in FY24. Net profit for FY25 stood at ₹583.42 crore, down marginally from ₹615.82 crore YoY, impacted by higher operating costs and tax provisions.
The company’s performance across its segments was strong: the domestic India business grew by 8% YoY to ₹545 crore, the US generics segment surged 20% YoY to ₹508 crore, and Ex-US generics grew 43% YoY, reaching ₹375 crore. The API segment showed a steady 4% YoY growth, contributing ₹342 crore.
EBITDA for the quarter increased by 9% YoY to ₹286 crore, with an EBITDA margin of 16%. Profit before tax stood at ₹191.95 crore, up from ₹182.85 crore in Q4FY24, reflecting solid operational efficiency.
Alembic Pharmaceuticals’ shares opened at ₹913.50 and reached a high of ₹913.50, with a low of ₹880.60. The stock is currently trading below its 52-week high of ₹1,303.90 and above its 52-week low of ₹725.20.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.